We have used time-resolved phosphorescence anisotropy (TPA) of actin to evaluate domains of dystrophin and utrophin, with implications for gene therapy in muscular dystrophy. Dystrophin and its homolog utrophin bind to cytoskeletal actin to form mechanical linkages that prevent muscular damage. Because these proteins are too large for most gene therapy vectors, much effort is currently devoted to smaller constructs. We previously used TPA to show that both dystrophin and utrophin have a paradoxical effect on actin rotational dynamicsrestricting amplitude while increasing rate, thus increasing resilience, with utrophin more effective than dystrophin. Here, we have evaluated individual domains of these proteins. We found that a "mini-dystrophin," lacking one of the two actin-binding domains, is less effective than dystrophin in regulating actin dynamics, correlating with its moderate effectiveness in rescuing the dystrophic phenotype in mice. In contrast, we found that a "micro-utrophin," with more extensive internal deletions, is as effective as full-length dystrophin in the regulation of actin dynamics. Each of utrophin's actin-binding domains promotes resilience in actin, while dystrophin constructs require the presence of both actinbinding domains and the C-terminal domain for full function. This work supports the use of a utrophin template for gene or protein therapy designs. Resilience of the actin-protein complex, measured by TPA, correlates remarkably well with previous reports of functional rescue by dystrophin and utrophin constructs in mdx mice. We propose the use of TPA as an in vitro method to aid in the design and testing of emerging gene therapy constructs.
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We have used time-resolved phosphorescence anisotropy (TPA) of actin to evaluate domains of dystrophin and utrophin, with implications for gene therapy in muscular dystrophy. Dystrophin and its homolog utrophin bind to cytoskeletal actin to form mechanical linkages that prevent muscular damage. Because these proteins are too large for most gene therapy vectors, much effort is currently devoted to smaller constructs. We previously used TPA to show that both dystrophin and utrophin have a paradoxical effect on actin rotational dynamicsrestricting amplitude while increasing rate, thus increasing resilience, with utrophin more effective than dystrophin. Here, we have evaluated individual domains of these proteins. We found that a "mini-dystrophin," lacking one of the two actin-binding domains, is less effective than dystrophin in regulating actin dynamics, correlating with its moderate effectiveness in rescuing the dystrophic phenotype in mice. In contrast, we found that a "micro-utrophin," with more extensive internal deletions, is as effective as full-length dystrophin in the regulation of actin dynamics. Each of utrophin's actin-binding domains promotes resilience in actin, while dystrophin constructs require the presence of both actinbinding domains and the C-terminal domain for full function. This work supports the use of a utrophin template for gene or protein therapy designs. Resilience of the actin-protein complex, measured by TPA, correlates remarkably well with previous reports of functional rescue by dystrophin and utrophin constructs in mdx mice. We propose the use of TPA as an in vitro method to aid in the design and testing of emerging gene therapy constructs.
Introduction
Duchenne and Becker muscular dystrophies are caused by mutations in dystrophin, a 427-kDa protein localized to the cytoskeletal lattice of the sarcolemma. 1 Dystrophin's N-terminus binds to cytoskeletal actin, and the C-terminus (CT) binds to the dystroglycoprotein complex at the sarcolemma membrane (Fig. 1) . Lack of functional dystrophin in skeletal muscles results in disarray of the cytoskeletal organization at key structural regions in striated muscles, [6] [7] [8] disabling proper transmission or diffusion of lateral force 9, 10 and rendering the muscle susceptible to eccentric contraction damage. 11 Atomic force microscopy studies showed a decrease in myocyte stiffness due to lack of dystrophin. 12 A similar loss in stiffness was observed when cytochalasin D was applied to disrupt the actin cytoskeleton, indicating that the dystrophin-actin interaction plays a central role in maintaining mechanical stability in the muscle cytoskeleton. 12 Our goal is to elucidate the molecular mechanism by which the dystrophin-actin interaction contributes to the molecular mechanics of force transmission and to use this understanding to improve therapeutic strategies.
Utrophin is a 395-kDa dystrophin homolog that is present at the subsarcolemmal region, with functions similar to dystrophin in fetal or regenerating muscle (Fig. 1) . 8 As muscle fibers mature, utrophin is replaced by dystrophin, [13] [14] [15] but utrophin has been proposed as a viable therapeutic replacement in dystrophin-deficient mice. 16, 17 Both proteins contain a highly homologous N-terminal actin-binding domain (ABD1) consisting of tandem CH (calponin homology) motifs, followed by a central domain containing a series of triple-helical spectrin-type repeats (STRs), and a C-terminal (CT) region. 18, 19 However, dystrophin and utrophin have distinctly different lateral interactions with actin. 20 Dystrophin's second actin-binding domain (ABD2) is separated from ABD1 by 10 STRs, 21, 22 while utrophin's ABD2 is adjacent to ABD1 23, 24 ( Fig. 1) .
We previously used time-resolved phosphorescence anisotropy (TPA) of actin to determine how dystrophin and utrophin affect the structural dynamics of the actin filament (Fig. 1) . 5 We showed that the binding of dystrophin or utrophin decreases the amplitude (increases the order) of actin's rotational flexibility while also increasing the rate, both in a highly cooperative manner, thus creating a more resilient complex. 5 We found that utrophin is much more effective than dystrophin in increasing this resilience. The goal of the present study is to understand more clearly how the individual domains of dystrophin and utrophin influence these effects on the resilience of actin.
This goal is important for the rational design of gene therapy for muscular dystrophy, which is currently being developed using recombinant adeno-associated virus vectors. These vectors are size limited; thus, mini-and micro-versions of dystrophin and utrophin have been developed with large deletions of the central STR domains, including all or part of ABD2. [25] [26] [27] [28] Since these TRIT (therapeutically relevant internally truncated) constructs rely on less than a third of the fulllength protein, there is a need to evaluate how individual regions in dystrophin and utrophin affect their interaction with actin. The present study applies TPA to further evaluate the effects of isolated regions in dystrophin and utrophin through deletion constructs (Fig. 2) . 29, 30 Two TRIT constructs, referred to as mini-dystrophin (Mini-Dys in Fig. 2a ) and micro-utrophin (MicroUtr in Fig. 2b ), were selected due to the availability of consistent physiological studies in dystrophic (mdx) mice. 28, 31, 32 Additional deletion constructs, with either N-or C-terminal truncations, were engineered to test specific domains within dystrophin and utrophin (Fig. 2) . 29, 30 Our goal is to use TPA to (a) create a biophysical blueprint that identifies key regions in dystrophin and utrophin required to regulate actin microsecond structural dynamics, (b) investigate why the most promising therapeutic constructs have limited effects on rescuing the dystrophic phenotype in mice, and Each has an N-terminal actinbinding domain (ABD1, containing tandem CH domains) and a C-terminal domain (CT) that binds to the sarcolemma, with intervening STRs (ovals) and hinges (H). On the TPA timescale (1-1000 ms), the detected motions are dominated by twisting, 2,3 but the double-helical structure of the actin filament strongly couples its twisting and bending flexibility. 4 The ratio of rotational rate to amplitude, detected by TPA, defines the filament's resilience (see Methods), which is increased by both dystrophin and utrophin.
(c) establish TPA as a rapid in vitro method for selecting potential therapeutic dystrophin and utrophin constructs according to their ability to mimic the effects of full-length dystrophin on actin dynamics.
Results
Microsecond dynamics of actin in the presence of therapeutically promising mini-dystrophin To provide motivational context for this study, we begin with the mini-dystrophin construct ("MiniDys" in Figs. 2a and 3a) . 26, 29, 30, 33 This TRIT (designated DysΔH2-R19 because it lacks the portion from hinge H2 to STR19) is modeled after cases of mild Becker muscular dystrophy, in which up to 46% of the central STR region is missing but the patients can remain ambulatory past 60 years of age. [35] [36] [37] Despite the extensive internal deletions, leaving only eight STRs, this construct has shown high efficacy in rescuing the dystrophic phenotype in mdx mice. 26, 33, 38 To compare the TPA results independently of the different actin-binding affinities of the constructs used in this study, we report results as a function of the fractional saturation of binding sites on actin [ν = y/B max ; Eq. (7)].
2,5 Direct comparison of the TPA decays when actin binding is 50% saturated (ν = 0.5) shows that Mini-Dys is quite similar to full-length dystrophin (Dys) in its ability to regulate actin structural dynamics (Fig. 3b) . Indeed, Mini-Dys decreases the amplitude of rotational dynamics while decreasing the rate ( Fig. 3c and d), corresponding to increased actin resilience. This supports our hypothesis that increased actin (7)]. Curves show fits according to Eq. (8), yielding the degree of cooperativity (n). 3, 34 resilience is a key to the function of dystrophin or its therapeutic surrogates.
The TPA data were analyzed to determine amplitudes and rates [Eqs. (1)- (5)], which were plotted against ν and fitted with Eq. (8) . This yielded the cooperativity n, which is the number of actin protomers whose amplitudes and rates are affected by the binding to a single actin protomer ( Fig. 3c and  d ). These plots show that Mini-Dys is less effective than Dys at low ν values, primarily because its effect on amplitude is four times less cooperative (n = 2.5) than that of Dys (n = 9.6) (Fig. 3c ). This result suggests that Mini-Dys can restore normal actin resilience only at high expression levels, approaching that of Dys in wild-type (wt) mice.
Despite the efficacy of Mini-Dys in rescuing the dystrophic phenotype, its large size causes great challenges for delivery of gene or of protein into muscle using recombinant adeno-associated virus; 32 thus, its development has not progressed beyond small-animal testing. 26, 33, 38 "Micro" constructs (micro-TRITS, based on utrophin and dystrophin), which have larger internal truncations (typically leaving only four STRs instead of eight), are preferred for large-animal delivery. 26, 32, 39 To establish a rational basis for the design of micro-TRITs, we used several other deletion constructs ( Fig. 2) to investigate systematically the impact of specific regions in dystrophin and utrophin on actin structural dynamics.
Effects of end truncations in dystrophin and utrophin
The constructs of dystrophin containing end truncations (Fig. 4a) were found to retain partial capacity to restrict actin rotational amplitude (Fig.  4b ), but they have all lost the capacity to increase actin rotational rate (Fig. 4c) . Dp260, which lacks the N-terminal half of Dys (thus lacking ABD1) but retains the second actin-binding domain (ABD2) and the rest of the C-terminal third of Dys, is as cooperative as full-length Dys (n ∼ 10); but DNR17, which contains both actin-binding domains and lacks the C-terminal third, shows much lower cooperativity (n ∼ 2). Thus, the dystrophin C-terminal third, which does not interact directly with actin, appears to play an allosteric role in regulating actin dynamics. The cooperativity of this effect is more pronounced when ABD2 is present (Dp260; Fig. 4b , n ∼ 10) compared with ABD1 alone (mini-dystrophin; Fig. 3c , n ∼ 3). Isolated DysABD1 restricts actin Fig. 4 . TPA effects of end-truncation constructs (left, dystrophin; right, utrophin) on actin structural dynamics. In (a) and (d), black regions correspond to actin-binding domains. 20, 29, 30 Amplitudes (b and e) and Rates (c and f) of actin rotational dynamics are plotted against n [Eq. (7)]. The degree of cooperativity (n) [Eq. (8)] is indicated. 3, 34 rotational amplitude significantly at low ν, but its propensity to bundle actin at higher concentrations 40 prevented a complete analysis.
End truncations in utrophin (Fig. 4d ) also decrease its effectiveness on actin dynamics (Fig.  4e and f) . UNR10, containing both actin-binding domains but lacking the C-terminal third of Utr, has effects at high ν similar to those of full-length Utr but completely lacks cooperativity (Fig. 4e and  f) . The isolated ABD1 of Utr is about half as effective as UNR10 and also lacks cooperativity. These results suggest that (1) both actin-binding domains of Utr are important for full regulation of actin dynamics and that (2) the C-terminal portion of Utr appears to determine cooperativity even more clearly than in Dys.
Although deletions in both dystrophin and utrophin decrease their regulation of actin structural dynamics compared with full-length proteins, utrophin constructs retain more effectiveness in enhancing actin resilience. The truncated utrophins retain the capacity to enhance rate substantially, as well as to restrict amplitude ( Fig. 4e and f) , thus clearly enhancing resilience [Rate/Amplitude; Eq. (5)], while the truncated dystrophins enhanced rate (and hence resilience) only slightly ( Fig. 4b  and c) . These results support the use of a utrophin template for gene therapy designs to enhance actin resilience.
Effect of micro-utrophin on actin dynamics
To test the hypothesis that utrophin is a highly effective template for therapeutic designs, we evaluated a micro-utrophin therapy construct ("Micro-Utr" in Figs. 2 and 5 ). This micro-TRIT (designated UtrΔR4-21 because the segment from STR4 through STR21 has been deleted, leaving only four STRs) has been previously tested in mouse models. 41 TPA data show that Micro-Utr restricts actin rotational amplitude and increases rate with comparable cooperativity as full-length dystrophin or utrophin (Fig. 5b and c) . Although it is not as effective as full-length utrophin, it is more effective than dystrophin at all values of ν.
Effects of dystrophin and utrophin constructs on the resilience of actin
As explained in Methods, resilience of the actinprotein complex is measured from TPA as the ratio of rate to amplitude of actin rotational dynamics, normalized to that of actin alone [Eq. (5)].
5 Figure 6 shows plots of resilience versus ν, derived from data in Figs. 3-5 . We compared different constructs with regard to their maximum effect on actin resilience (Fig. 6c ) and the cooperativity of this effect (Fig. 6d) .
Resilience was increased by all constructs, but utrophin constructs were consistently more effective than their homologous dystrophin counterparts (e.g., compare Utr with Dys, UNR10 with DNR17, and Micro-Utr with Mini-Dys).
Utrophin's greater capacity than dystrophin, for increasing actin's resilience, correlates well with previous studies of the utrophin's rescue of muscle mechanics in the dystrophin-null mdx mouse. Full mechanical function can be restored by upregulation of utrophin at half the level of dystrophin in wt muscle. 17, 20, 23, 33 Similarly, atomic force microscopy analysis of dystrophic myocytes showed that utrophin upregulation can restore cellular stiffness to wt levels at 28% of the wt dystrophin level. 12 This correlation between TPA-measured actin resilience and muscle function also extends to results from physiological tests in mdx mice, as discussed below.
Discussion
Deletions in dystrophin and utrophin decrease their effectiveness in regulating actin structural dynamics. However, since utrophin and its constructs are more effective than the dystrophin counterparts, large deletions in utrophin produced structural regulation similar to that of full-length dystrophin, showing great promise for utrophin as a therapeutic surrogate.
The domains of dystrophin TPA shows that both DNR17 (containing the N-terminal two-thirds of Dys, including both actin-binding domains) and Dp260 (containing the C-terminal one-third of Dys, including ABD2) restrict actin rotational amplitude (Fig. 4b) but have little effect on rate (Fig. 4c) and thus have little effect on resilience ( Fig. 6a and c) , while Mini-Dys (containing both N-and C-termini but lacking ABD2) has effects on both amplitude (Fig.  3c) and rate (Fig. 3d) , thus enhancing resilience nearly and full-length Dys (Fig. 6a and c) . However, the cooperativity of Mini-Dys on actin is less than that of Dys (Fig. 6d) , and the highly cooperative restriction of amplitude by Dp260 (Fig. 4b) suggests that the C-terminal region, especially in conjunction with ABD2, is essential for cooperativity in Dys-actin interactions. Thus, the two separated actin-binding domains in dystrophin affect actin structural dynamics with distinctly different but interlacing effects.
The domains of utrophin
Despite their high sequence homology, utrophin's domains have effects on actin structural dynamics that are distinct from those of dystrophin. In general, utrophin's effects are simpler-for example, all four utrophin constructs decrease amplitude to a similar extent that they increase rate (Figs. 4 and 5) ; thus, it is sufficient to look at the effects on resilience (Rate/Amplitude) (Fig. 6 ). Another key difference is that utrophin does not require any of its C-terminal half after STR10 to enhance actin's resilience, since the N-terminal UtrABD1 has substantial effects on its own, and UNR10 (lacking the C-terminal half of Utr) has nearly identical effects as full-length Utr at high ν values (Fig. 6b and c) . However, neither of these N-terminal constructs (UtrABD1 and UNR10) regulates actin structural dynamics cooperatively ( Fig. 6b and d) . Since Micro-Utr (which does contain the C-terminus of Utr) shows cooperativity comparable to that of Utr ( Fig. 6b and d ), it appears that the C-terminal region of Utr, like that of Dys, is essential for conferring cooperativity.
In contrast to dystrophin, the effects of the two actin-binding domains in utrophin appear to be identical and additive. UtrABD1 enhances actin resilience by a factor of 2.3, UNR10 (containing both ABD1 and ABD2 but lacking the C-terminal half) enhances actin resilience by a factor of 5 (Fig. 6) , and Micro-Utr (containing ABD1 plus 30% of ABD2) enhances actin resilience by a factor of 2.94 (30% more than UtrABD1). Thus, the regulation of actin structural dynamics by utrophin constructs appears to be simpler and more predictable than that for utrophin constructs. Coupled with the higher efficacy of Utr construct compared with Dys constructs, this result argues for utrophin as a template for therapeutic design.
TPA as a rapid in vitro measure of therapeutic efficacy
We surveyed previous physiological studies on mdx mice with transgenic expression of dystrophin and utrophin. 17, 33 For meaningful comparison of resilience with physiological findings, we considered only studies that tested the mechanical function (specific isometric force) of treated dystrophic muscles, reported levels of expression in the tested muscles, and had tested the animals at the same age. Despite large numbers of studies performed on dystrophic mouse models, few studies meet these standards. However, we found two studies that consistently measured the isometric specific force in diaphragm muscles in mdx mice at 3-4 months of age 17, 33 (Fig. 7a) . These studies included the Fio and Fer mouse lines that expressed full-length utrophin at 54% and 27% of the endogenous dystrophin level, respectively, in a dystrophin-null background (mdx). 17, 20, 42 A recovery score with regard to the isometric specific force in these mice was calculated based on preclinical standard operating procedures established by TREAT-NMD [Eq. (9)]. [43] [44] [45] As explained in Methods, resilience values were calculated using data in Fig. 6a and b, to correct for the reported protein expression levels and actin affinities. Correlation plots relating recovery scores of wt muscles (100% recovery with 100% dystrophin) and dystrophic muscles (0% recovery with 0% dystrophin) treated with different levels of dystrophin or utrophin showed a distinctively high correlation to the relative resilience calculated by TPA studies (R = 0.98). The remarkably linear relationships between the resilience of the actin cytoskeleton and the observed specific force (Fig. 7a) suggest that the measurement of resilience by TPA is a potentially useful in vitro predictor of the therapeutic efficacy of dystrophin and utrophin constructs.
Our measured resilience also demonstrated excellent correlation with mechanical restoration of dystrophic muscles treated with Mini-Dys 32 and Micro-Dys 28, 41 (Fig. 7b , R = 0.99). Although the micro-utrophin construct demonstrated a larger effect on increasing actin resilience compared to wt dystrophin at saturating levels (Fig. 6c) , the mdx study did not achieve saturating expression levels in the tested muscles. 28 As a result, the resulting relative resilience calculated based on the level of micro-utrophin expression reported and on our data ( Fig. 6a and b) was lower than that expected for Dys (wt), in which actin is saturated with full-length dystrophin. This further supports the use of TPA as a rapid in vitro method to screen proposed gene therapy constructs for potential therapeutic efficacy.
Our results suggest the feasibility of using utrophin as a therapeutic surrogate. Figure 6c shows that utrophin constructs consistently provided higher resilience compared with dystrophin constructs. Even Micro-Utr provided higher resilience compared with full-length dystrophin, despite extensive internal deletions. Thus, the same level of resilience can be achieved with lower concentrations of utrophin constructs compared with dystrophin constructs. This is consistent with the finding that expression of full-length utrophin at half the concentration of wt dystrophin was sufficient to fully restore muscle mechanics. 17 Since improving the transfection efficacy of these therapeutic constructs is still an ongoing pursuit, our data suggest that it would be most beneficial to use a utrophinderived construct. Coupled with possible immunogenicity in dystrophin-derived therapeutic constructs, 46 these results argue for the use of utrophin as a template for gene therapy designs.
Conclusion
We have used TPA to draw a biophysical blueprint of dystrophin and utrophin regarding their effects on actin structural dynamics and resilience. The domains of dystrophin and utrophin have different effects on actin, despite their high structural homology. Utrophin constructs are generally more robust in making actin resilient, despite large deletions. Compared with dystrophin constructs, utrophin constructs are more effective in enhancing actin resilience, and the effects of their domains on actin resilience are simpler and more independent, facilitating rational design. We find a strong correlation between resilience of actinprotein complexes and functional restoration reported from previous studies in mdx mice. We propose to use TPA as a rapid in vitro screening method for designing and testing the next generation of gene therapy constructs for muscular dystrophy.
Methods Protein preparation
Larger dystrophin and utrophin constructs including DNR17, UNR10, Dp260, and DysΔH2-R19 were expressed using Sf9 insect cells infected with high-titer recombinant N-terminal FLAG tags. 26, 29, 30 FLAG-MicroUtr was engineered by recombinant PCR using FLAGUtr cDNA as a template with identical primers as previously described. 28 Proteins were purified by FLAG affinity chromatography and dialyzed against two changes of phosphate-buffered saline (pH 7.5) to remove excess FLAG peptide. DysABD1 and UtrABD1 are expressed in Escherichia coli BL21 AI cell line and purified using a cation exchange (HiTrap SP XL; GE) for DysABD1 and an anion exchange (HiTrap Q XL; GE) for UtrABD1 followed by a size-exclusion column (Sephadex S200; GE). Proteins were concentrated in Millipore Amicon ultracentrifuge-based concentrators with cutoffs of either 100 kDa or 10 kDa depending on protein molecular mass. Concentrations were determined by Bradford protein assay with a bovine serum albumin standard.
Time-resolved phosphorescence anisotropy
Actin preparation and labeling with phosphorescent erythrosine iodoacetamide (ErIA) (Anaspec) was as described in Ref. 5 . Phalloidin-stabilized ErIA-actin was diluted in U/D buffer [100 mM NaCl 2 , 2 mM MgCl 2 , 0.2 mM ATP, 1 mM DTT, and 10 mM Tris (pH 7.5)] to 1 μM. Increasing concentrations of dystrophin and utrophin constructs were added to bind to 1 μM ErIAactin. Oxygen removing system containing of glucose oxidase (55 μg/ml), catalase (36 μg/ml), and glucose (45 μg/ml) was added to the sample prior to each experiment and incubated for 5 min to prevent photobleaching. 47, 48 The phosphorescent dye is excited at 532 nm with a vertically polarized 1.2-ns laser pulse from a FDSS 532-150 laser (CryLas) with a 100-Hz repetition rate. Emission was detected through a 670-nm-glass cutoff filter (Corion) using a photomultiplier (R928; Hamamatsu) and a transient digitizer (CompuScope 14100; GaGe) with a resolution of 1 μs per channel. Time-resolved anisotropy is defined by
where I v (t) and I h (t) are the vertically and horizontally polarized components of the detected phosphorescent emission, using a single detector at 90°and a rotating sheet polarizer alternating between the two orientations every 500 laser pulses. G is a correction factor calibrated by detection of the signal with horizontally polarized excitation and correcting so that the anisotropy is zero. TPA experiments were recorded with 30 cycles, each consisting of 500 pulses in each polarization. Anisotropy decays were analyzed by fitting to the sum of two exponential terms. 2, 5 Results were validated by comparison of residuals and chi-squared values of the fits at one, two, and three exponential terms, with the best fit consistently requiring two exponential terms.
The overall angular amplitude of rotational motion was defined as the radius of a cone calculated from the wobblein-cone model. 
Thus, a maximally flexible actin filament would exhibit a final anisotropy value of r ∞ = 0, yielding, and a cone angle of θ c = 90°, and a rigid filament would have r ∞ = r 0 (no decay) and θ c = 0°(no detectable rotation). The mean rate of actin filament rotational motions was defined as the inverse of the mean correlation time:
Resilience is defined as the maximum amount of elastic energy per unit volume that can be stored without large structural distortions to the protein complex. 49 Highly resilient polymers can recover quickly from deformations. During this process, the system stores mechanical energy from deformation as elastic energy. 50 Resilience of the actin-bound complex is determined from TPA as:
where Amplitude is calculated from Eq. (3), and Rate is calculated from Eq. (4). 5 The plotted resilience values of Fig. 6 are "Relative Resilience," normalized to the value observed for actin alone in the same study.
TPA-derived parameters (Amplitude, Rate, or Resilience) are plotted against the fractional saturation of actin binding (ν = bound protein molecules per binding site on actin). These ν values were determined from actin-binding assays of dystrophin and utrophin constructs using highspeed co-sedimentation. 5, 51 Varying concentrations of dystrophin or utrophin constructs were added to 6 μM labeled actin, incubated for 30 min at 20°C, and centrifuged at 100,000g for 20 min. The resulting pellets and supernatants were analyzed by SDS-PAGE to determine the concentrations of free and actin-bound protein. Then K d (dissociation constant in micromolars) and B max (number of protein-binding sites per actin protomer) were determined by fitting the data with
where y is the moles of bound protein per mole of actin, 
where [P T ] is the total concentration of protein added to labeled actin, and ν is the fractional saturation of actinbinding sites used in the horizontal axes of Figs. 3-6 .
Cooperativity
The degree of cooperativity was determined by fitting the plot of rotational Amplitude [Eq. 
where X(ν) is the observed value (Amplitude, Rate, or Resilience), X 0 is the value for actin only (ν = 0), X max is the value when actin is fully saturated (ν = 1), ν = y/B max [Eq. (7)] is the fraction of actin sites occupied by added protein, and n is the degree of cooperativity in the system, that is, the number of actin protomers affected by the binding of a single actin protomer. In other words, the number of actin protomers affected dynamically by the binding of one protein molecule in each experiment is n B max .
Correlation with preclinical data
In order to correlate resilience, as measured by TPA, with specific force measured in mice (Fig. 7) , we normalized resilience according to the level of expressed constructs, relative to dystrophin in the wt mouse, reported from each mouse study. 17, 28, 32 The concentration of dystrophin in wt mouse muscle was calculated from previous reports. 20, 52 Dystrophin comprises 0.026% of total muscle protein, 20 which amounts to 0.12 μM with a cellular density of 0.2 g/ml. 52 We assume a sarcolemmal surface area-to-cell volume ratio of 0.103 μm 2 /μm 3 53 and a length of 120 nm in the z-dimension (length of the dystrophin molecule). 23 Thus, the estimated local concentration of dystrophin is 9.9 μM in the wt mouse. Similarly, the concentration of cytoskeletal γ-actin at the subsarcolemmal region (using a total γ-actin concentration of 0.20 μM reported in the whole cell) 52 was calculated to be 16 μM. Since one dystrophin molecule interacts with 27 actin protomers with submicromolar affinity, 20 we assume that the fraction of dystrophin-decorated actin at the costamere is 1 (ν = 1). To normalize the relative resilience of each construct to the reported percentage of expression levels in each study, we use Eq. (7) to calculate the fractional saturation ν for each construct, based on their respective K d and B max values. 20 The resilience of the actin cytoskeleton was determined from this value of ν, using the plots in Fig. 6a and b .
To compare the mechanical function of treated muscles across studies, we used the preclinical standard operating procedure to calculate a recovery score, based on measurements of isometric specific force: [43] [44] [45] Recovery 
where m is the number of samples, and x i and y i are the values of specific force and actin resilience. x and y are the mean values, and σ x and σ y are the standard deviations.
